Melissa Leichter: My Team Used AI to Pinpoint Likely Undiagnosed Patients with Glanzmann’s Thrombasthenia
Melissa Leichter, Rare Disease Executive at Novo Nordisk, shared on LinkedIn:
”I’ve had a number of conversations recently with commercial colleagues about AI, and we’re all struck by how dramatically it can change patient outcomes.
For people living with an undiagnosed disease, getting clarity on their condition can stretch on for years.
Their life quickly becomes a marathon of misdiagnoses, trying to find the right specialists, waiting for openings on those doctors’ schedules, insurance delays, and other hurdles to clear.
AI, with its ability to parse vast amounts of data and surface patterns that otherwise would remain hidden, can significantly shorten that painful journey.
I’ve seen this in action in a rare disease context.
My team used AI to pinpoint likely undiagnosed patients with Glanzmann’s Thrombasthenia, an ultra-rare platelet disorder, by analyzing a blend of diagnostic codes, medication usage, and procedure records.
We were able to illuminate complex data that could trigger an earlier intervention.
We need to do more to unleash AI as a tool in patient diagnosis, and the biggest obstacle to that is data fragmentation.
Health record systems rarely talk to each other, even within a single institution, resulting in disconnected pockets of patient information.
Moving forward, it’s essential that we invest in data connectivity and unified patient journeys.
Only then can machine learning help us shrink the timeline between debilitating symptoms and life-changing diagnoses at scale — and improve the lives of countless patients.”
Read the full article here.
Article: How Sanford Health Embeds AI into Its EHR to Catch Disease Earlier and Personalize Care
Authors: Katie Adams
Stay updated with Hemostasis Today.
-
Nov 27, 2025, 16:00Nathan Connell on WFH AI Summaries from the Global Forum
-
Nov 27, 2025, 15:49Piotr Czempik: Rethinking Coagulation in Acute Liver Dysfunction
-
Nov 27, 2025, 15:35Overwhelmed? A Leader’s Guide from Mark Crowther to Getting Back on Track
-
Nov 27, 2025, 15:10Wolfgang Miesbach’s Top 10 Picks for TTP and Thrombosis from ASH 2025
-
Nov 27, 2025, 14:24ICCBBA’s Executive Director Eoin McGrath Chairs a Dynamic Session on AI, Innovation and Informatics in Transfusion Medicine
-
Nov 27, 2025, 13:26Wolfgang Miesbach’s Top 10 Picks for Bleeding Disorders from ASH 2025
-
Nov 27, 2025, 11:19Priya Prasad Presents a Case of Severe Hypotensive Transfusion Reaction
-
Nov 27, 2025, 04:07Eugene Tang Presents Highlights from UK Stroke Forum 2025
-
Nov 27, 2025, 03:47Michael Makris: I Believe the Time Has Come to Consider Emicizumab Up Front in Persons with Acquired Hemophilia